Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.